Business
Total Voting Rights
SkinBioTherapeutics plc has announced an update to its total voting rights, stating that following the admission of 129,736 new ordinary shares to satisfy share option exercises, the company now has 258,909,199 Ordinary Shares in issue. This updated figure of 258,909,199 will serve as the denominator for shareholders determining their notification obligations under the FCA's Disclosure Guidance and Transparency Rules. Disclaimer*
About this update from Skinbiotherapeutics Plc
SkinBioTherapeutics plc ("SkinBioTherapeutics" or "the Company") Total Voting Rights Following the admission today of 129,736 new ordinary shares of 1 pence each to satisfy the exercise of share options, the Company has 258,909,199 Ordinary Shares in issue. This figure of 258,909,199 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. -Ends- For more information please contact: SkinBioTherapeutics plc Stuart J. Ashman, CEO Emily Bertram, CFO +44 (0) 191 495 7325 Singer Capital Markets (Nominated Adviser & Broker) Philip Davies James Todd Patrick Weaver +44 (0) 020 7496 3000 Vigo Consulting (financial press) Rozi Morris, Melanie Toyne-Sewell +44 (0) 20 7390 0230 [email protected] Notes to Editors About SkinBioTherapeutics plc SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix ® , is based upon discoveries made by the translational dermatology team at the University of Manchester. The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix ® ) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix ® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores . The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products. The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com .
View stock analysis, news, and events for Skinbiotherapeutics Plc